USA flag logo/image

An Official Website of the United States Government

Modified bacterial system for vivo direction evolution

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71657
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
GM071252
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
POTENTIA PHARMACEUTICALS, INC
POTENTIA PHARMACEUTICALS, INC 201 E JEFFERSON ST, STE 312 LOUISVILLE, KY 40202
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Modified bacterial system for vivo direction evolution
Agency: HHS
Contract: 1R43GM071252-01
Award Amount: $252,798.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of this proposal is to develop a new genetic system that will mimic the natural process of evolution for a selected subset of genes inside of a bacterial cell. Instead of an evolutionary time scale of years, evolution will proceed at an accelerated rate and data will be collected in a matter of days. In addition to providing a powerful system to study evolution in the laboratory, such a system will form the core of a directed evolution technology. Directed evolution is an approach that enables scientists to "tune" the properties of enzymes for specific applications. Its benefit has become so apparent that today most new enzymes undergo some type of directed evolution before being commercialized. However, all current implementations of directed evolution are conducted step-wise, with each step in the evolution process necessitating a substantial amount of time and manpower. A single cycle of evolution usually takes a few days and involves demanding technical work at each step. Because enzymes usually need to undergo many cycles of evolution, each application can take a substantial amount of time. This proposal will yield a continuous in vivo directed evolution platform requiring only minimal external input. Such an evolution platform will enable scientists to conduct more than 20 cycles of evolution in the course of a single day. It thus has the potential to be 10X faster than current evolution technologies, 10X cheaper, easier to implement, and yield proteins that will theoretically be better optimized than those produced today. Such a system will enable the optimization of proteins for various industrial applications (catalysts for pharmaceutical chemical synthesis is one example), but more importantly, it will be adapted to mammalian systems to enable the in vivo evolution of peptide-based therapeutics (such as antibodies, cyclic peptides, and enzymes). These therapeutics will address critical areas such as antiviral and antimicrobial drugs.

Principal Investigator:

Paul K. Olson
5022954607
P0OLSO01@LOUISVILLE.EDU

Business Contact:

Cedric Francois
5022954607
FRANCOIS@POTENTIAPHARMA.COM
Small Business Information at Submission:

POTENTIA PHARMACEUTICALS
POTENTIA PHARMACEUTICALS 1434 GODDARD AVE LOUISVILLE, KY 40204

EIN/Tax ID: 043575012
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No